Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial-Reference-Cited by-同舟云学术

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

Published:2014-09 Issue:9949 Volume:384 Page:1196-1205
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

PD MED Collaborative Group

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Systematic review of incidence studies of Parkinson's disease;Twelves;Mov Disord,2003

2. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London;Schrag;BMJ,2000

3. Parkinson's disease: drug therapy;Oertel;Baillieres Clin Neurol,1997

4. Levodopa and the progression of Parkinson's disease;Fahn;N Engl J Med,2004

5. Dopamine agonist therapy in early Parkinson's disease;Stowe;Cochrane Database Syst Rev,2008

Cited by 294 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of crocin on movement disorders and oxidative DNA damage in Parkinson's disease: Insights from a randomized controlled trial;Parkinsonism & Related Disorders;2024-09

2. Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models;Molecular Therapy - Nucleic Acids;2024-09

3. Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization;npj Parkinson's Disease;2024-08-28

4. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta‐Analysis;Movement Disorders Clinical Practice;2024-08-27

5. The PM20D1-NADA pathway protects against Parkinson’s disease;Cell Death & Differentiation;2024-08-22